HPTN 035

A multi-center clinical trial evaluating the safety and effectiveness of two different candidate microbicides, BufferGel® and PRO 2000, in 3,100 sexually active HIV-negative women at seven sites in Africa and the United States. Results have been reported. (See news release below.)

See

Microbicide Trials Network statement on the results of MDP 301 [1]

Dec 14, 2009

What Happens Next: Understanding the results of HPTN 035 and MDP 301 and the promise of ARVs for HIV prevention [2]

Dec 14, 2009

Trial finds microbicide promising as HIV prevention method for women [3]

Feb 9, 2009

HPTN 035 Backgrounder [4]

HPTN 035 Fact Sheet [5]

HPTN 035 Q&A [6]

See Also

HPTN 035 Study Protocol [7]

NIAID Press Release on HPTN 035 Results [8]

Feb 9, 2009

Watch

CROI presentation of results [9]

Feb 9, 2009

Links:
[1] http://www.mtnstopshiv.org/node/1595
[2] http://www.mtnstopshiv.org/node/1594
[3] http://www.mtnstopshiv.org/node/765
[4] http://www.mtnstopshiv.org/news/studies/hptn035/backgrounder
[5] http://www.mtnstopshiv.org/news/studies/hptn035/facts
[6] http://www.mtnstopshiv.org/news/studies/hptn035/qa
[7] http://www.mtnstopshiv.org/sites/default/files/attachments/HPTN035v3.pdf
[8] http://www3.niaid.nih.gov/news/newsreleases/2009/HPTN_035_gel.htm
[9] http://tinyurl.com/dc7dng